紫杉醇脂质体或紫杉醇注射液联合顺铂治疗宫颈癌的疗效与安全性差异的临床观察

中国药物警戒 ›› 2016, Vol. 13 ›› Issue (12): 712-715.

紫杉醇脂质体或紫杉醇注射液联合顺铂治疗宫颈癌的疗效与安全性差异的临床观察

陈姝彤

南京医科大学附属淮安第一医院,江苏淮安 223001

收稿日期:2017-01-13 修回日期:2017-01-13 出版日期:2016-12-20 发布日期:2017-01-13
作者简介:陈姝彤,女,硕士,妇科肿瘤临床诊疗。

Clinical Observation of Curative Effect and Safety Differences of Paclitaxel Liposome or Paclitaxel Injection Combined with Cisplatin Treatment for Cervical Cancer

CHEN Shu-tong

Huai'an First People's Hospital, Nanjing Medical University, Jiangsu Huai'an 223001, China

Received:2017-01-13 Revised:2017-01-13 Online:2016-12-20 Published:2017-01-13

摘要/Abstract

摘要： 目的比较紫杉醇脂质体或紫杉醇注射液联合顺铂治疗中晚期宫颈癌的临床效果与安全性差异。方法选取2009年6月~ 2010年6月在我院诊治的中晚期宫颈癌患者83例,随机分为观察组42例和对照组41例,观察组第1天给予紫杉醇脂质体135 mg·m^-2静脉滴注,第2天给予顺铂60 mg·m^-2静脉滴注;对照组第1天给予紫杉醇注射液135 mg·m^-2静脉滴注,第2天给予顺铂60 mg·m^-2静脉滴注。两组患者皆采取同步放化疗方案,比较两组患者治疗宫颈癌的临床效果（近期疗效和远期疗效）及安全性差异。结果观察组治疗宫颈癌的有效缓解率为83.33%,对照组为68.29%,差异有统计学意义（P<0.05）;观察组的宫颈癌旁浸润和淋巴结转移显著低于对照组,5年生存率显著高于对照组（P<0.05）;观察组在脱发、胃肠道反应、过敏反应、骨髓抑制及免疫力下降等不良反应方面与对照组相比存在显著安全性差异（P<0.05）。结论紫杉醇脂质体联合顺铂治疗宫颈癌的近期疗效和远期疗效良好,且安全性相对较高。

关键词: 紫杉醇脂质体, 紫杉醇注射液, 顺铂, 宫颈癌

Abstract: Objective To observe the clinical effect and safety differences of paclitaxel liposome or paclitaxel injection combined with cisplatin in patients with middle and advanced cervical cancer. Methods 83 cases of patients with middle and advanced cervical cancer from June 2009 to June 2010 in our hospital were enrolled as study subjects and randomly divided into two groups, 42 cases in observation group and 41 cases in control group. Observation group was given paclitaxel liposome 135 mg·m^-2via intravenous drip on the first day, cisplatin 60 mg·m^-2 was given via intravenous drip on the second day; control group was given paclitaxel injection 135 mg·m^-2 via intravenous drip on the first day, cisplatin 60 mg·m^-2was given via intravenous drip on the second day. The two groups all took concurrent radiochemotherapy scheme. The clinical effect (recent curative effect and the forward curative effect) and safety differences between two groups in the treatment of cervical cancer were compared. Results The effective alleviation rates of observation group and control group were 83.33% and 68.29% respectively, the difference was statistically significant (P<0.05). The cervical cancer invasion and lymph node metastasis of observation group was significantly lower than control group, and the 5-year survival rate of the observation group was significantly higher than the control group (P<0.05). The adverse drug reaction such as alopecia, gastrointestinal reaction, anaphylactic reaction, myelosuppression and weakened immunity in observation group has significant differences compared with the control group (P<0.05). Conclusion In this study, paclitaxel liposome combined with cisplatin has good recent curative effect and forward curative effect and safety is relatively high in the treatment of cervical cancer.

Key words: paclitaxel liposome, paclitaxel injection, cisplatin, cervical cancer

中图分类号:

R979.1

陈姝彤. 紫杉醇脂质体或紫杉醇注射液联合顺铂治疗宫颈癌的疗效与安全性差异的临床观察[J]. 中国药物警戒, 2016, 13(12): 712-715.

CHEN Shu-tong. Clinical Observation of Curative Effect and Safety Differences of Paclitaxel Liposome or Paclitaxel Injection Combined with Cisplatin Treatment for Cervical Cancer[J]. Chinese Journal of Pharmacovigilance, 2016, 13(12): 712-715.

参考文献

[1] McKim A, Walter A C, Sheely K M, et al. An economic analysis of cisplatin alone versus cisplatin doublets in the treatment of women with advanced or recurrent cervical cancer[J]. European journal of gynaecological oncology, 2016, 37(3): 353-356.
[2] Cho O, Chun M, Chang S J, et al. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer[J]. Anticancer Research, 2016, 36(7): 3541-3547.
[3] Heijkoop S T, van Doorn H C, Stalpers L J, et al. Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation[J]. International Journal of Hyperthermia the Official Journal of European Society for Hyperthermic Oncology North American Hyperthermia Group, 2014, 30(1): 6-10.
[4] Petrelli F, Stefani A D, Raspagliesi F, et al. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis[J]. Gynecologic Oncology, 2014, 134(1): 166-171.
[5] Zeng S, Li L, Zhong M, et al. A randomized controlled trial of two chemotherapy regimens-paclitaxel liposome combined with platinum and paclitaxel combined with platinum in concurrent chemoradiotherapy for cervical carcinoma[J]. Chinese-German Journal of Clinical Oncology, 2012, 33(2):113-116.
[6] 路萍, 宋俊标. 紫杉醇脂质体联合顺铂同步放化疗治疗宫颈癌的疗效观察[J]. 医学综述, 2012, 18(23): 4056-4058.
[7] 高晓兰, 朱增强. 顺铂新辅助化疗联合扶正驱邪中药治疗晚期宫颈癌的临床疗效研究[J]. 中国妇幼保健, 2014, 29(5): 691-693.
[8] Martínez-Fernández M I, Legaspi F J, Valtueña P G, et al. Long- Term Results of a Phase II Trial of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer[J]. International Journal of Gynecological Cancer, 2016, 26(6): 1162-1168.
[9] 董存山. 紫杉醇脂质体联合顺铂同步放化疗治疗宫颈癌的疗效观察[J]. 中国现代药物应用, 2014,(19): 131-133.
[10] Mabuchi S, Isohashi F, Yokoi T, et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes[J]. Gynecologic Oncology, 2016, 141(2): 240-246.
[11] Lorvidhaya V, Chitapanarux I, Phromratanapongse P, et al. Phase Ⅱ study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer[J]. Gan to Kagaku RyohoCancer & Chemotherapy, 2010,37(7): 1271-1275.
[12] 冯中亚. 卡培他滨与博来霉素分别联合顺铂治疗宫颈癌的效果观察[J]. 治疗与观察, 2016, 20(10): 183.
[13] Petrić M B, Boraska J T, Strikic A, et al. Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy[J]. International Journal of Gynecological Cancer, 2015, 25(2): 315-319.
[14] Li Y, Wang X, Li J, et al. Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer[J]. European Journal of Gynaecological Oncology,2015, 36(1): 54-58.
[15] 王怀方. 紫杉醇脂质体联合铂类同步放化疗治疗宫颈癌的疗效及安全性[J]. 山东医药, 2015, 55(5): 89-90.
[16] 蒋亚齐, 袁一枫, 陈丽. 紫杉醇脂质体联合奈达铂同步放化疗治疗局部晚期食管癌疗效观察[J]. 山东医药, 2014, 54(2): 55-57.
[17] 张兰, 李彦辉, 王彩霞,等. 紫杉醇脂质体的制备及初步毒性、药效学研究[J]. 中国药学杂志, 2013, 48(6): 446-449.
[18] 曹珍珍, 唐迪红, 夏蛮,等. 紫杉醇脂质体与顺铂周疗方案同步放疗治疗中晚期宫颈癌的疗效比较[J]. 肿瘤药学, 2015, 5(2):116-119.